IP Library Granted Patent US 10,434,150
Granted Patent B2
US 10,434,150 · App. 14/762,423 · Granted Oct 8, 2019

Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance

Inventors: Bret Berner (Half Moon Bay, CA); Matthew John Siegel (Menlo Park, CA)
Assignee: Immunogenics LLC
A61K38/4873A23L33/10A61K9/0053A61K9/0095A61K9/08A61K9/2018A61K38/482A61K47/12A61K47/183A61K47/186A61K47/22A61K47/26A23V2002/00C12N9/50C12Y304/21026C12Y304/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,434,150
App. No.
14/762,423
Granted
Oct 8, 2019
Kind
B2
Abstract

Oral administration of ALV003 can protect celiac disease patients and patients otherwise suffering from gluten-intolerance from the harmful effects of ingesting food containing gluten.

Claims (13)

1. A unit dosage form with ALV003 enzyme in an amount ranging from 100 mg to 6 g, wherein said unit dosage form is in three stickpacks:

a first stickpack containing ALV001 or ALV001*, and 0.002-0.02 g sodium metabisulfite;

a second stickpack containing ALV002;

a third stickpack containing artificial sweetener, 0.01-0.1 g cysteine, a flavoring and 0.5-2 g potassium citrate;

wherein the unit dose form comprises as excipients 0.5-2 g sodium citrate and 0.1-1 g citric acid split between said three stickpacks; and wherein said first and second stickpack do not comprise hygroscopic artificial sweeteners, cysteine and potassium citrate.

2. The unit dosage form of claim 1 , wherein said unit dosage form contains between 0.5-2 g sodium citrate and 0.1-1 g citric acid, split between the first and second stickpacks and between 0.5-2 g potassium citrate and 0.01-0.1 g cysteine in the third stickpack.

3. The unit dosage form of claim 1 , wherein the third stickpack comprises 0.01-0.5 g sucralose as artificial sweetener.

4. A unit dosage form of ALV003 divided into three stickpacks or sachets, wherein:

a first stickpack or sachet comprises from 150 mg to no more than 600 mg of ALV001*;

a second stickpack or sachet comprises from 150 mg to no more than 600 mg of ALV002;

wherein the first and second stickpacks or sachets combined comprise from 204 mg to no more than 263 mg of citric acid, and from 817 mg to no more than 842 mg citrate present as a salt form; wherein 8 mg of sodium metabisulfite is present in said first stickpack or sachet; and wherein the total amount of sodium in the first and second stickpacks is no more than 800 mg; and

a third stickpack or sachet comprising 0.3 to 200 mg artificial sweetener selected from sucralose, aspartame, and neotame, 25 to 1500 mg flavoring, 815 to 1815 mg potassium citrate, 185-440 mg citric acid, and about 100 mg cysteine;

wherein the first and second stickpack or sachet do not comprise hygroscopic artificial sweetener, cysteine, and potassium citrate.

Assignments (3)
SECURITY INTEREST Recorded Oct 14, 2022
From: IMMUNOGENX, INC.
To: MATTRESS LIQUIDATORS, INC.
Reel/Frame 061429/0816 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2016
From: ALVINE PHARMACEUTICALS, INC.
To: IMMUNOGENICS LLC
Reel/Frame 039060/0975 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2015
From: BERNER, BRET; SIEGEL, MATTHEW JOHN
To: ALVINE PHARMACEUTICALS, INC.
Reel/Frame 036152/0872 →
Continuity (2)
Provisional Application 61755583 · Jan 23, 2013
Related Publication 20150352195A1 · Dec 10, 2015
Cited By (1)
US 12,582,601